Worldwide Usa Cancer Immunotherapy Market Segmentation, Application Analysis and Market Forecast 2017 – Acute Market Reports

This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 11 chapters supported by 114 tables and 41 figures over 256 pages.

Browse Full Report Visit –

  • An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies.
  • Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
  • Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
  • Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market).
  • Insight into the various immunotherapeutics available for specific cancer types.
  • Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
  • Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
  • Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
  • Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe.
  • Summary table to identify the category of immunotherapy drug offered by the 76 companies.

The report is supported by 155 tables & figures over 246 pages. This report is presented as follows:

The global market for cancer immunotherapy by the following sub-categories are presented:

  • By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
  • By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors
  • By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)

A comprehensive account of company product portfolios are provided for 78 Cancer Immunotherapy pharma and biotech companies including:

  • Amgen Inc.
  • Biogen Idec Inc.x
  • Bristol-Myers Squibb Co.
  • Cellectis
  • Cellerant Therapeutics Inc.
  • Celldex Therapeutics
  • Eli Lilly and Co.
  • EMD Serono Inc.
  • Genentech Inc.
  • Genmab AS
  • GlaxoSmithKline
  • ImmunoGen Inc.

Browse All Reports of This Category –

1.0 Executive Summary

1.1 Objectives of Report

1.1 Key Questions Answered in this Report

1.2 Data Sources and Methodology

2.0 Cancer Immunotherapy: An Overview

2.1 Human Immune System

2.1.1 Components of Human Immune System

2.2 Types of Cancer Immunotherapy

2.3 Monoclonal Antibodies (Mabs) to Treat Cancer

2.3.1 Most Frequently Targeted Antigens by MAbs

2.4 Types of Monoclonal Antibodies (MAbs)

2.4.1 Naked MAbs

2.4.2 Conjugated Monoclonal Antibodies Components of an Antibody Drug Conjugate (ADC) Mechanism of Action of Antibody Drug Conjugate (ADC) The Cytotoxic Warheads used in ADCs Successful Cytotoxin Warheads

3.0 Current Status of Cancer Immunotherapy: An Overview

3.1 Programmed Death (PD-1) Inhibitors

3.1.1 Important Events and Advantages for Nivolumab in Melanoma Indication

3.1.2 Important Events and Advantages for Nivolumab in Non-Small Cell Lung Cancer

3.1.3 Important Events and Advantages for Nivolumab in Renal Cell Cancer

3.1.4 Nivolumab Studies for Melanoma

3.1.5 Nivolumab Studies for Non-Small Cell Lung Cancer (NSCLC)

3.1.6 Nivolumab Studies for Renal Cell Cancer (RCC)

3.2 MK-3475 (Pembrolizumab)

3.2.1 Important Events and Advantages for MK-3475 in Melanoma

4.0 Challenges in Cancer Medicine Research: An Overview

4.1 Years of Failures and Emerging Successes in Melanoma Medicine Research

4.1.1 Future Outlook for Melanoma Drugs

4.2 A New Era for Lung Cancer Medicines

4.2.1 Progresses Made in Lung Cancer Medicine Research

4.2.2 Successes and Failures in Lung Cancer Medicine Development

4.2.3 Future Outlook for Lung Cancer Medicines

4.3 Ray of Hope for Brain Cancer Patients

About – Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.

Contact Us :

Name : Chris Paul


Designation : Global Sales Manager

Toll Free(US/CANADA): +1-855-455-8662

Email :

Website :

Designed by
Powered by
%d bloggers like this: